Healthcare provider profile · identity verified

Daniel G Glascock, MD

Family Practice · CEDAR FALLS, IA · NPI 1972580892

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	870	222
Lisinopril	Lisinopril	324	92
Levothyroxine Sodium	Levothyroxine Sodium	288	75
Omeprazole	Omeprazole	240	64
Amlodipine Besylate	Amlodipine Besylate	238	64
Meloxicam	Meloxicam	178	36
Rosuvastatin Calcium	Rosuvastatin Calcium	176	49
Tamsulosin Hcl	Tamsulosin Hcl	169	43
Metformin Hcl	Metformin Hcl	160	40
Hydrochlorothiazide	Hydrochlorothiazide	153	41
Furosemide	Furosemide	142	34
Losartan Potassium	Losartan Potassium	140	40
Gabapentin	Gabapentin	137	41
Pantoprazole Sodium	Pantoprazole Sodium	135	32
Atenolol	Atenolol	132	28
Metoprolol Succinate	Metoprolol Succinate	124	38
Simvastatin	Simvastatin	122	37
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	119	31
Metoprolol Tartrate	Metoprolol Tartrate	119	32
Montelukast Sodium	Montelukast Sodium	112	23
Potassium Chloride	Potassium Chloride	110	25
Finasteride	Finasteride	96	25
Warfarin Sodium	Warfarin Sodium	81	12
Fluoxetine Hcl	Fluoxetine Hcl	79	19
Jardiance	Empagliflozin	78	15
Escitalopram Oxalate	Escitalopram Oxalate	76	22
Pravastatin Sodium	Pravastatin Sodium	76	16
Alendronate Sodium	Alendronate Sodium	75	17
Clopidogrel	Clopidogrel Bisulfate	75	17
Fluticasone Propionate	Fluticasone Propionate	75	21
Glipizide	Glipizide	75	17
Ezetimibe	Ezetimibe	73	21
Duloxetine Hcl	Duloxetine Hcl	65	19
Allopurinol	Allopurinol	64	14
Trulicity	Dulaglutide	64	12
Carvedilol	Carvedilol	51	suppressed
Eliquis	Apixaban	48	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	48	14
Venlafaxine Hcl Er	Venlafaxine Hcl	47	11
Albuterol Sulfate Hfa	Albuterol Sulfate	43	18
Ibuprofen	Ibuprofen	43	suppressed
Metformin Hcl Er	Metformin Hcl	43	14
Trazodone Hcl	Trazodone Hcl	43	13
Pioglitazone Hcl	Pioglitazone Hcl	42	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	41	suppressed
Paroxetine Hcl	Paroxetine Hcl	41	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Memantine Hcl	Memantine Hcl	36	suppressed
Sertraline Hcl	Sertraline Hcl	36	14
Diclofenac Sodium	Diclofenac Sodium	35	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Xarelto	Rivaroxaban	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Famotidine	Famotidine	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	suppressed
Gemfibrozil	Gemfibrozil	31	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Terazosin Hcl	Terazosin Hcl	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	11
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Topiramate	Topiramate	27	suppressed
Fenofibrate	Fenofibrate	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	11
Donepezil Hcl	Donepezil Hcl	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Ozempic	Semaglutide	24	suppressed
Alprazolam	Alprazolam	23	11
Bupropion Xl	Bupropion Hcl	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Spiriva Handihaler	Tiotropium Bromide	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Sildenafil Citrate	Sildenafil Citrate	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Celecoxib	Celecoxib	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Lovastatin	Lovastatin	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	13
Valacyclovir	Valacyclovir Hcl	18	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Dutasteride	Dutasteride	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Naproxen	Naproxen	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	12	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	12	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	12	suppressed
Imipramine Hcl	Imipramine Hcl	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Piroxicam	Piroxicam	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Budesonide Dr	Budesonide	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Ursodiol	Ursodiol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error